Displaying drugs 626 - 650 of 9450 in total
Nonacog beta pegol
Nonacog beta pegol is a recombinant coagulation factor IX derivative. It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) molecule for peptide activation by a site-directed glycoPEGylation. Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). Nonacog...
Approved
Investigational
Matched Description: … [L41185] Nonacog beta pegol was approved by Health Canada on November 29, 2017.[L43682] ... It is produced without animal-derived materials and with an attached 40kDa polyethylene glycol (PEG) …
Indigotindisulfonic acid
Indigotindisulfonic acid is a blue-colored dye with a variety of uses.[A32490,A32491,A32492,L2222] Its salt form, indigotindisulfonate sodium, is also known as indigo carmine, indigotine or FD&C Blue #2. This compound is an acid-base indicator and is used in the production of food colorants and pH tests. Indigotindisulfonic acid is used in...
Approved
Investigational
Matched Description: … This compound is an acid-base indicator and is used in the production of food colorants and pH tests. ... [A32490,A32491,A32492] In 2022, the FDA approved the intravenous use of indigotindisulfonate sodium to …
Apronalide
Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura .
Approved
Matched Description: … Apronalide is approved in Japan. …
Azelastine
Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic conjunctivitis.[L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first...
Approved
Matched Description: … Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment ... of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic conjunctivitis …
Solriamfetol
Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label].
Approved
Matched Categories: … Antidepressive Agents …
Ombitasvir
Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common...
Approved
Investigational
Matched Description: … direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an ... Ombitasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly [FDA ... First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without …
Dermatophagoides farinae
Dermatophagoides farinae extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.
Approved
Matched Description: … This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue …
Dermatophagoides pteronyssinus
Dermatophagoides pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies.
Approved
Matched Description: … This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue …
Flurbiprofen
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis....
Approved
Investigational
Matched Description: … Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic …
Safinamide
Safinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Approved
Investigational
Matched Description: … It was approved in Europe in February 2015, and in the United States on March 21, 2017. …
Matched Categories: … Antidepressive Agents …
Matched Categories: … Antidepressive Agents …
Guanfacine
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
Approved
Investigational
Matched Description: … receptor agonist initially indicated for the treatment of hypertension[L11274] but is now indicated as an …
Morphine
Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength...
Approved
Investigational
Trichlormethiazide
A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Approved
Vet approved
Telmisartan
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to...
Approved
Investigational
Matched Description: … Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. …
Matched Mixtures name: … Truemed Group LLC …
Matched Mixtures name: … Truemed Group LLC …
Poliovirus type 1 antigen (formaldehyde inactivated)
Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were...
Approved
Investigational
Poliovirus type 2 antigen (formaldehyde inactivated)
Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 2. The vaccine contains purified and inactivated poliovirus type 2 that were...
Approved
Investigational
Poliovirus type 3 antigen (formaldehyde inactivated)
Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 3. The vaccine contains purified and inactivated poliovirus type 3 that were...
Approved
Investigational
Hydralazine
Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a...
Approved
Matched Description: … [T691]
Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779] …
Pretomanid
Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy...
Approved
Matched Description: … [A182915] Pretomanid is an antimycobacterial agent that is administered with [Bedaquiline] and [Linezolid …
Bepotastine
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available...
Approved
Matched Description: … The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. ... Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus …
Ripretinib
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Description: … [L13769]
It is the first drug approved as a fourth-line therapy in the specific setting of prior ... Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved …
Nirsevimab
Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ΔΈ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry...
Approved
Investigational
Matched Description: … infants experiencing their first RSV season, whereas palivizumab requires five monthly doses to cover an ... [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 ... [A254571,L44146]
On November 2022, nirsevimab was approved by the EMA for the prevention of RSV lower …
Displaying drugs 626 - 650 of 9450 in total